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Conclusions Cardiac fibrosis, hypertrophy and diastolic dys-
function are enhanced in miR-214 KO animals. The mecha-
nisms of this observation are not caused by mir214 effects in
cardiac fibroblasts, but through other mechanisms that need to
be further addressed.
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Introduction Angiopoietin 1 (Ang1) is a growth factor that
plays a crucial role in maintaining normal vascular function.
The main role of Ang1 is to maintain vessels in quiescent,
inhibit vascular inflammation and maintain endothelial sur-
vival. Ang1 exerts its protective effect by activating Tie2
receptors, which are predominantly expressed on endothelial
cells. The ratio between Tie2 and its co-receptor, Tie1, is a
regulatory factor in Ang1 signalling with high levels of Tie1
capable of reducing Ang1-induced Tie2 activation. The activity
of Ang1 is aided by Tie2 phosphorylation followed by activa-
tion of cascade of downstream signalling pathways including
Phosphatidylinositol 3-kinase (PI3Kinase)/AKT and Erk1/2.
Interleukin 1 Beta (IL1b) is a proinflammatory cytokine that
acts on microvasculature and large vessels and has been impli-
cated in a range of vascular pathologies including vascular
inflammation and atherosclerosis. Various pathophysiological
mediators including VEGF and TNF alpha have shown to
affect the levels of Tie receptor expression and subsequently
influencing Ang1 signalling in endothelial cells; however the
involvement of Interleukin 1 Î² on this pathway has not been
reported.
Aim To examine the impact IL1b has on Tie2:Tie1 expression
ratio and Angiopoietin1 signalling in endothelial cells.
Method Primary Human umbilical vein endothelial cells
(HUVEC) were stimulated with 25 ng/ml of IL1b at different
time periods in the presence or absence of 300 ng/ml of
human recombinant Ang1. Cell lysates from the treated cells
were then subjected to immunoprecipitation and Western blot-
ting to analyse Tie receptor levels and signalling molecules
associated with Ang1 cellular transduction including Phospho-
Tie2 (pTie2), and phospho-AKT (pAKT).The levels of target
proteins were compared between reactions by quantifying
mean intensity of bands. Data is presented as means and SEM
of three independent experiments. Statistical significance repre-
sented with p<0.05 using Students t test.
Results The expression of Tie2 and Tie1 protein in endothelial
cells treated with IL1b was significantly altered with different
Tie2:Tie1 ratio patterns observed at 1 hour and 24 hour.
These changes to the Tie2:Tie1 expression patterns also
altered the ability of Ang1 to induce Tie2 phosphorylation
and downstream signalling molecules including pAKT.
Conclusion This study demonstrates for the first time that
IL1b is capable of altering Tie2:Tie1 ratio that subsequently
leads to the regulation of Ang1 signalling. These findings pro-
vide further insight on how the Angiopoietin1 signalling path-
way adapts to the acute and chronic effect of IL1b and how
this signalling pathway is important in limiting pro-inflamma-
tory responses of the vasculature.
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Introduction Ischaemic preconditioning (IPC) limits infarct size
(IS) through the activation of the PI3K-AKT signal cascade,
known as the RISK pathway. The identification of the roles of
individual PI3K isoforms should aid in the development of
isoform-specific agents with improved cardioprotection. We
aimed to elucidate the role of the PI3Ka isoform in
cardioprotection.
Methods Male C57BL/6 mice were randomly allocated
between groups in isolated perfused Langendorff experiments
subjected to 35 min ischaemia and 2 hour reperfusion. Two
distinct PI3Ka-isoform specific inhibitors (3mM of G326 and
BYL719) were administered during the IPC protocol (4-cycles
of 5 min ischaemia and 5 min reperfusion), or at reperfusion.
PI3K activity was measured by Western blot analyses of AKT
phosphorylation. Insulin was used as PI3Ka canonical activa-
tor. In addition, these studies were also undertaken using an
in vivomouse model. Finally, expression of PI3Ka protein lev-
els was evaluated by Western blot in whole mouse heart and
human atrial tissues (REC No. 00/0275), as well as in primary
adult ventricular mouse cardiomyocytes and mouse cardiac
endothelial cell (MCEC) line.
Results In the isolated Langendorff-perfused model, IPC
reduced IS compared to control (49±4% vs 23±2%,
p<0.001). Protection was not abolished using either G326 (26
±3%) or BYL719 (25±3%) when administered during IPC
(Figure 1A) despite the phosphorylation of AKT being inhib-
ited. Interestingly, these same isoform inhibitors did block pro-
tection when given at reperfusion (G326 50±3%; BYL719 47
±4%) (Figure 1B), in addition to blocking the AKT phosphor-
ylation revealing a distinct role for the PI3Ka isoform during
the early moments of reperfusion. Neither drug affected IS on
its own. In support, the canonical PI3Ka activator, insulin,
when given at reperfusion reduced myocardial IS compared to
control (25±2 vs 55±4%, p<0.001) and this protection was
abolished by G326 (Figure 2A). These experiments were con-
firmed in vivo when using the PI3Ka isoform inhibitor at
reperfusion to block IPC protection (Figure 2B). On a tissue
level, PI3Ka is expressed at the same level in mouse heart
and human atrium. Interestingly, PI3Ka levels in MCEC were
about 3-fold higher compared to adult ventricular mouse car-
diomyocytes (p=0.047).
Conclusions Using a targeted pharmacological approach, we
have demonstrated that the PI3KÎ± isoform is required during
the reperfusion phase for protection conferred by IPC. The
translational perspective is highlighted by the observation that
human heart tissue expresses PI3KÎ±. This suggests that strat-
egies specifically enhancing the ± isoform of PI3 kinase at
reperfusion promotes tissue salvage and, as such, could pro-
vide an attractive target for clinical treatment of ischaemia-
reperfusion injury.
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